Search Results

Inotrem announced the outcome of its regulatory interactions with the US Food and Drug Administration to finalize the design of a single Phase 3 registration trial for nangibotide in septic shock.

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.

Inotrem announced the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine.

Selexis SA , a JSR Life Sciences company, and Inotrem SA , an advanced clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations.

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD.

Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time at the International Sepsis Forum held in Barcelona the results for its Phase IIb ASTONISH clinical trial in septic shock patients.

Inotrem announced at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress.

Inotrem announced a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program.

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.